Assessment and management of imminent fracture risk in the setting of the fracture liaison service

Kassim Javaid, M., Harvey, Nicholas, McCloskey, Eugene V., Kanis, John A. and Cooper, Cyrus (2022) Assessment and management of imminent fracture risk in the setting of the fracture liaison service. Osteoporosis International, 33 (6), 1185-1189. (doi:10.1007/s00198-021-06284-9).

Record type: Editorial

Text

Javaid IFR editorial_clean v3 - Accepted Manuscript

Available under License University of Southampton Accepted Manuscript Licence.

Download (100kB)

More information

Accepted/In Press date: 21 December 2021

e-pub ahead of print date: 14 March 2022

Published date: June 2022

Additional Information: Funding Information: J.A.K., N.C.H. and E.V.M. are responsible for the creation and maintenance of FRAX but derive no financial benefit. E.V.M. has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi Aventis, UCB, Viiv, Warner Chilcott and I3 Innovus. C.C. reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. N.C.H. has received consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma. M.K.J. reports personal fees from UCB, Amgen and Kyowa Kirin. J.A.K. reports no additional competing interests. Copyright: Copyright 2022 Elsevier B.V., All rights reserved.

Learn more about Institute for Life Sciences research